In addition to therapeutic effects of SGLT2 inhibitors on liver dysfunction, steatosis and/or steatohepatitis in humans30–32 and mice11–17, our observation suggests that SGLT2 inhibitors have preventive effects on a full spectrum of NAFLD in conditions of obesity, insulin resistance, and dyslipidemia. The gene discussed is SLC5A2; the disease is steatosis.